Dr. Mary Claire Haver

It's too expensive.

So we're going to start later to see if there's cardiovascular benefit because these women aren't going to have heart attacks until they're in their 70s or 80s.

So...

To save money.

And that made sense.

They were also tracking multiple factors.

They were looking at frailty scores, all kind of stuff.

So here we go with this study.

And we have two arms.

We have women who have uteruses and women who don't.

Two groups, okay?

The women with uteruses got estrogen and progestogen or placebo.

And then the other group got estrogen only because they don't have a uterus or placebo.

Here we go.

So remember, average age 63.

They see that.

versus placebo, the rate in breast cancer went from four out of a thousand women per year to five out of a thousand women per year on the medication.

So that is a 25% increase in relative risk, not absolute risk, relative risk.

They stopped the study, called a press conference before the paper was published, before any physician could look at it.

It was the number one news story, medical news story of 2002.